BRAIN Biotech AG

XTRA:BNN Stock Report

Market Cap: €71.0m

BRAIN Biotech Dividends and Buybacks

Dividend criteria checks 0/6

BRAIN Biotech does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.8%

Buyback Yield

Total Shareholder Yield-0.8%
Future Dividend Yield0%
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

New Narrative Mar 02

Production Disruptions And Weak Margins Will Eventually Benefit Consolidated Enzyme Platform

Catalysts About BRAIN Biotech BRAIN Biotech AG is a European industrial biotechnology company that develops and produces enzyme based and bio based solutions for food, beverages and other industrial applications. What are the underlying business or industry changes driving this perspective?
New Narrative Feb 06

Biological Solutions And Gene Editing Will Reshape Industrial Processes Over The Next Decade

Catalysts About BRAIN Biotech BRAIN Biotech develops and produces enzyme and microbial solutions for industrial and pharmaceutical applications. What are the underlying business or industry changes driving this perspective?
Analysis Article Jan 18

Analysts Have Been Trimming Their BRAIN Biotech AG (ETR:BNN) Price Target After Its Latest Report

It's shaping up to be a tough period for BRAIN Biotech AG ( ETR:BNN ), which a week ago released some disappointing...
Analysis Article Dec 22

Market Cool On BRAIN Biotech AG's (ETR:BNN) Revenues Pushing Shares 28% Lower

BRAIN Biotech AG ( ETR:BNN ) shares have retraced a considerable 28% in the last month, reversing a fair amount of...
Analysis Article Nov 07

It's A Story Of Risk Vs Reward With BRAIN Biotech AG (ETR:BNN)

With a median price-to-sales (or "P/S") ratio of close to 0.6x in the Chemicals industry in Germany, you could be...
Analysis Article Aug 26

Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Jul 23

A Piece Of The Puzzle Missing From BRAIN Biotech AG's (ETR:BNN) 38% Share Price Climb

BRAIN Biotech AG ( ETR:BNN ) shares have had a really impressive month, gaining 38% after a shaky period beforehand...
Analysis Article Nov 12

Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 27% Bounce

BRAIN Biotech AG ( ETR:BNN ) shares have continued their recent momentum with a 27% gain in the last month alone. Not...
Analysis Article Sep 24

Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 50% Bounce

BRAIN Biotech AG ( ETR:BNN ) shares have had a really impressive month, gaining 50% after a shaky period beforehand...
Analysis Article Aug 06

BRAIN Biotech AG (ETR:BNN) Screens Well But There Might Be A Catch

With a median price-to-sales (or "P/S") ratio of close to 0.7x in the Chemicals industry in Germany, you could be...
Analysis Article Jun 29

Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Apr 19

BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate

Key Insights Using the 2 Stage Free Cash Flow to Equity, BRAIN Biotech fair value estimate is €4.43 Current share price...
Analysis Article Mar 28

BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable

When close to half the companies in the Chemicals industry in Germany have price-to-sales ratios (or "P/S") below 0.7x...
Analysis Article Feb 16

Is BRAIN Biotech (ETR:BNN) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Sep 13

Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if BNN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BNN's dividend payments have been increasing.


Dividend Yield vs Market

BRAIN Biotech Dividend Yield vs Market
How does BNN dividend yield compare to the market?
SegmentDividend Yield
Company (BNN)n/a
Market Bottom 25% (DE)1.5%
Market Top 25% (DE)4.6%
Industry Average (Chemicals)3.8%
Analyst forecast (BNN) (up to 3 years)0%

Notable Dividend: Unable to evaluate BNN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BNN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate BNN's payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BNN has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/08 00:12
End of Day Share Price 2026/05/08 00:00
Earnings2025/12/31
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BRAIN Biotech AG is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yi-Dan WangDeutsche Bank
Jan KochDeutsche Bank
Jan KochDeutsche Bank